Yasmeen Rahimi
Stock Analyst at Piper Sandler
(3.89)
# 638
Out of 5,240 analysts
103
Total ratings
41.58%
Success rate
13.83%
Average return
Main Sectors:
Stocks Rated by Yasmeen Rahimi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Maintains: Overweight | $48 → $60 | $19.85 | +202.27% | 2 | May 11, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Overweight | $105 → $192 | $75.95 | +152.80% | 2 | May 8, 2026 | |
| ANAB AnaptysBio | Maintains: Overweight | $95 → $93 | $62.69 | +48.36% | 3 | May 4, 2026 | |
| TRAX First Tracks Biotherapeutics | Initiates: Overweight | $54 | $18.43 | +193.00% | 1 | May 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Overweight | $22 → $40 | $29.22 | +36.89% | 1 | Apr 16, 2026 | |
| TVRD Tvardi Therapeutics | Maintains: Neutral | $4 → $3 | $3.95 | -24.05% | 2 | Apr 1, 2026 | |
| PLRX Pliant Therapeutics | Maintains: Overweight | $4 → $3 | $1.17 | +156.41% | 3 | Mar 12, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $72 → $25 | $8.26 | +202.66% | 3 | Mar 4, 2026 | |
| CLYM Climb Bio | Initiates: Overweight | $23 | $11.41 | +101.58% | 1 | Feb 13, 2026 | |
| KRRO Korro Bio | Upgrades: Overweight | $11 → $30 | $11.20 | +167.86% | 3 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $450 → $1,200 | $346.84 | +245.98% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $6.75 | +122.22% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $73 | $19.14 | +281.40% | 1 | Jan 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $1.87 | +1,236.90% | 1 | Dec 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $540 → $900 | $518.87 | +73.45% | 5 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $63.18 | +18.71% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $36 | $9.60 | +275.00% | 5 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $78 | $32.31 | +141.41% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $11.91 | +67.93% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $5.54 | +369.31% | 1 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $145 | $52.95 | +173.84% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 | $33.76 | +51.07% | 4 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $6 | $2.44 | +145.90% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $93 | $84.58 | +9.96% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $75 | $9.36 | +701.28% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $37 | $37.75 | -1.99% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 | $4.80 | +441.67% | 2 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $280 | $12.95 | +2,062.16% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 | $37.48 | +158.80% | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $76 | $28.81 | +163.80% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 | $3.02 | +727.81% | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.65 | +157.51% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $6 → $12 | $15.62 | -23.18% | 2 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $8.51 | +957.58% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $0.34 | +4,265.54% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $16 | $5.27 | +203.61% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $93 | $38.08 | +144.22% | 3 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $57 | $29.25 | +94.87% | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $67 | $7.60 | +781.58% | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $20 | $0.40 | +4,951.78% | 5 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $103.88 | -66.31% | 3 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $87 | $14.03 | +520.10% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $175 | $6.67 | +2,523.69% | 4 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $72 | $77.22 | -6.76% | 5 | Jun 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $0.96 | +4,068.84% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $420 | $15.02 | +2,696.27% | 1 | Aug 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $77 | $109.16 | -29.46% | 1 | Jul 31, 2020 |
Avalo Therapeutics
May 11, 2026
Maintains: Overweight
Price Target: $48 → $60
Current: $19.85
Upside: +202.27%
Nektar Therapeutics
May 8, 2026
Maintains: Overweight
Price Target: $105 → $192
Current: $75.95
Upside: +152.80%
AnaptysBio
May 4, 2026
Maintains: Overweight
Price Target: $95 → $93
Current: $62.69
Upside: +48.36%
First Tracks Biotherapeutics
May 4, 2026
Initiates: Overweight
Price Target: $54
Current: $18.43
Upside: +193.00%
Roivant Sciences
Apr 16, 2026
Maintains: Overweight
Price Target: $22 → $40
Current: $29.22
Upside: +36.89%
Tvardi Therapeutics
Apr 1, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $3.95
Upside: -24.05%
Pliant Therapeutics
Mar 12, 2026
Maintains: Overweight
Price Target: $4 → $3
Current: $1.17
Upside: +156.41%
Arcturus Therapeutics Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $72 → $25
Current: $8.26
Upside: +202.66%
Climb Bio
Feb 13, 2026
Initiates: Overweight
Price Target: $23
Current: $11.41
Upside: +101.58%
Korro Bio
Jan 29, 2026
Upgrades: Overweight
Price Target: $11 → $30
Current: $11.20
Upside: +167.86%
Jan 28, 2026
Maintains: Overweight
Price Target: $450 → $1,200
Current: $346.84
Upside: +245.98%
Jan 28, 2026
Initiates: Overweight
Price Target: $15
Current: $6.75
Upside: +122.22%
Jan 27, 2026
Initiates: Overweight
Price Target: $73
Current: $19.14
Upside: +281.40%
Dec 29, 2025
Initiates: Overweight
Price Target: $25
Current: $1.87
Upside: +1,236.90%
Dec 19, 2025
Maintains: Overweight
Price Target: $540 → $900
Current: $518.87
Upside: +73.45%
Dec 18, 2025
Initiates: Overweight
Price Target: $75
Current: $63.18
Upside: +18.71%
Oct 28, 2025
Maintains: Overweight
Price Target: $15 → $36
Current: $9.60
Upside: +275.00%
Oct 6, 2025
Initiates: Overweight
Price Target: $78
Current: $32.31
Upside: +141.41%
Sep 8, 2025
Initiates: Overweight
Price Target: $20
Current: $11.91
Upside: +67.93%
Aug 27, 2025
Initiates: Overweight
Price Target: $26
Current: $5.54
Upside: +369.31%
Apr 24, 2025
Maintains: Overweight
Price Target: $93 → $145
Current: $52.95
Upside: +173.84%
Apr 2, 2025
Maintains: Overweight
Price Target: $51
Current: $33.76
Upside: +51.07%
Mar 7, 2025
Maintains: Overweight
Price Target: $10 → $6
Current: $2.44
Upside: +145.90%
Jan 23, 2025
Initiates: Overweight
Price Target: $93
Current: $84.58
Upside: +9.96%
Nov 5, 2024
Initiates: Overweight
Price Target: $75
Current: $9.36
Upside: +701.28%
Sep 23, 2024
Reiterates: Overweight
Price Target: $37
Current: $37.75
Upside: -1.99%
Sep 19, 2024
Maintains: Overweight
Price Target: $26
Current: $4.80
Upside: +441.67%
Jul 16, 2024
Reiterates: Overweight
Price Target: $280
Current: $12.95
Upside: +2,062.16%
Jul 2, 2024
Maintains: Overweight
Price Target: $97
Current: $37.48
Upside: +158.80%
Jun 26, 2024
Initiates: Overweight
Price Target: $76
Current: $28.81
Upside: +163.80%
Jun 21, 2024
Maintains: Overweight
Price Target: $25
Current: $3.02
Upside: +727.81%
Jun 13, 2024
Initiates: Overweight
Price Target: $30
Current: $11.65
Upside: +157.51%
May 7, 2024
Upgrades: Overweight
Price Target: $6 → $12
Current: $15.62
Upside: -23.18%
Apr 4, 2024
Initiates: Overweight
Price Target: $90
Current: $8.51
Upside: +957.58%
Mar 27, 2024
Maintains: Overweight
Price Target: $15
Current: $0.34
Upside: +4,265.54%
Mar 4, 2024
Maintains: Overweight
Price Target: $7 → $16
Current: $5.27
Upside: +203.61%
Oct 27, 2023
Maintains: Overweight
Price Target: $58 → $93
Current: $38.08
Upside: +144.22%
Oct 24, 2023
Maintains: Overweight
Price Target: $28 → $57
Current: $29.25
Upside: +94.87%
Aug 8, 2023
Initiates: Overweight
Price Target: $67
Current: $7.60
Upside: +781.58%
Jul 21, 2023
Maintains: Overweight
Price Target: $13 → $20
Current: $0.40
Upside: +4,951.78%
Jul 3, 2023
Reiterates: Overweight
Price Target: $35
Current: $103.88
Upside: -66.31%
Feb 8, 2023
Maintains: Overweight
Price Target: $87
Current: $14.03
Upside: +520.10%
Jan 17, 2023
Maintains: Overweight
Price Target: $75 → $175
Current: $6.67
Upside: +2,523.69%
Jun 10, 2022
Maintains: Overweight
Price Target: $50 → $72
Current: $77.22
Upside: -6.76%
Aug 24, 2021
Initiates: Overweight
Price Target: $40
Current: $0.96
Upside: +4,068.84%
Aug 26, 2020
Initiates: Overweight
Price Target: $420
Current: $15.02
Upside: +2,696.27%
Jul 31, 2020
Initiates: Overweight
Price Target: $77
Current: $109.16
Upside: -29.46%